ADC Therapeutics
ADCT
74 hedge funds and large institutions have $164M invested in ADC Therapeutics in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 8 closing their positions.
468% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $201K
463% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 8
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
100% more funds holding
Funds holding: 37 → 74 (+37)
11.81% more ownership
Funds ownership: 42.04% → 53.85% (+12%)
5% more capital invested
Capital invested by funds: $156M → $164M (+$7.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$17.2M |
| 2 |
BlackRock
New York
|
+$14.1M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$10M |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$5.15M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$5.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.49M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.62M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.25M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.09M |
| 5 |
Millennium Management
New York
|
-$771K |
ADCT Hedge Fund Activity: Q2 2024 in Review
74 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2024, worth a combined $164M — up 5.1% from $156M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ADCT positions and 8 closed out — a net gain of 37 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $17.2M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $4.49M sold.
- 74 institutional investors held ADC Therapeutics (ADCT) as of Q2 2024, up from 37 in Q1 2024.
- Funds reported $164M of ADC Therapeutics stock for Q2 2024, up 5.1% quarter-over-quarter.
- 45 funds opened new ADC Therapeutics positions in Q2 2024 and 8 closed out, a net change of +37 holders.
- The largest ADC Therapeutics buyer in Q2 2024 was OrbiMed, an estimated $17.2M added.
- The largest ADC Therapeutics seller in Q2 2024 was Adage Capital Partners, an estimated $4.49M sold.
Based on aggregated 13F filings for Q2 2024.